TELA Bio Stock

TELA Bio Equity

The The Equity of TELA Bio (TELA) as of Aug 15, 2026 is 6.31 M USD. In the previous year, The Equity was 28.46 M USD — a change of -77.82% (lower).

Equity

6.31 MUSD

YoY

-77.82%

Last updated:

In 2026, TELA Bio's equity was 6.31 M USD, a -77.82% increase from the 28.46 M USD equity in the previous year.

Access this data via the Eulerpool API

TELA Bio Stock analysis

What does TELA Bio do? TELA Bio Inc is an American medical technology company that specializes in the development and manufacture of innovative surgical implants. The history of this company began in 2012 when a group of experienced bioengineers and medical professionals decided to develop a better surgical tissue replacement material. The idea was to create a product that not only supports the healing process but is also safe, durable, and easy to handle. Over the years, TELA Bio has successfully implemented the business model of complete vertical integration, which means that the company takes care of everything from research and development to production, distribution, and marketing of its products. This allows the company to build closer relationships with its customers and improve the quality of its products by addressing the needs and requirements of its users. The core business of TELA Bio focuses on a wide range of surgical tissue replacement materials specifically designed for plastic and reconstructive surgery, hernia repair, and wound healing. These products are characterized by their high biocompatibility, strength, and flexibility, and provide a safe and effective solution for a variety of medical applications. Key products offered by TELA Bio include the OviTex® product family, which includes surgical mesh materials for supporting wound healing in hernia repairs and abdominal surgeries, as well as tissue replacement materials for breast reconstruction after mastectomy. These products are known for their high biocompatibility and ability to integrate into the surrounding tissue and restore natural tissue structures. In addition, TELA Bio also offers the TELADERM®-DH product, specifically developed for wound healing in diabetes patients. This product consists of a tissue replacement material that supports skin repair and reduces the risk of infection, particularly in patients with poorly healing wounds. Overall, TELA Bio has developed a wide range of products tailored to the needs of modern medicine. The company is focused on improving the quality of medical care and providing innovative solutions for surgical wound healing. With its successful implementations in research, production, and distribution, TELA Bio is well-positioned to continue growing and solidify its position as a leading provider of medical implants. TELA Bio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing TELA Bio's Equity

TELA Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding TELA Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating TELA Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

TELA Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in TELA Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about TELA Bio stock

The Equity of TELA Bio is 6.31 M USD in 2026.

The Equity of TELA Bio changed from 28.46 M USD to 6.31 M USD, representing a -77.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity TELA Bio since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's TELA Bio historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — TELA Bio

All Key Metrics — TELA Bio